Our Recent Posts

Archive

Checkpoint Surgical Receives FDA Breakthrough Designation for Nerve Regeneration Device

Checkpoint Surgical, Inc., a leader in hand-held, intraoperative neurostimulation technology for nerve protection and repair, announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for the Checkpoint brief electrostimulation therapy (BEST) system. The Checkpoint BEST™ system is designed to provide electrical stimulation of peripheral nerves to promote nerve regeneration as an adjunct to surgical intervention following nerve injury, with the goal of accelerating and improving patient recovery. “We are pleased to receive the Breakthrough Device designation from the FDA as it will allow Checkpoint Surgical to deliver this important innovation

 Follow us:

Email us:

Mutual Capital Partners

1290 Bassett Rd  Suite #7

 Westlake, OH 44145

©2020 by Mutual Capital Partners